Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This Amendment No. 2 amends the Current Reports on Form 8-K and Form 8-K/A of Genesis Biopharma, Inc. filed with the Securities and Exchange Commission on August 11, 2011 and October 13, 2011, respectively (the “Reports”). The Form 8-K/A of Genesis Biopharma, Inc. included the Cooperative Research and Development Agreement referred to in the initial Form 8-K filed on August 11, 2011, but did not include Annex A thereto. Annex A was omitted based upon a request for confidential treatment filed with the Securities and Exchange Commission. The request for confidential treatment has been withdrawn, and the enclosed Cooperative Research and Development Agreement includes Annex A. The information reported in the Reports is incorporated
by reference into this amendment.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibit is included as part of this report.
10.1
Cooperative Research and Development Agreement for Intramural-PHS Clinical Research, dated August 5, 2011, between the U.S. Department of Health and Human Services, as represented by the National Cancer Institute, and Genesis Biopharma, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
